Placental Growth Factors Market Growing Valuation of US$ 64.6 Million Predicted by 2033

The placental growth factors market is anticipated to reach a valuation of US$ 34.9 million by 2023. Over the course of the forecast period, the market is anticipated to grow at a 6.3% CAGR and reach US$ 64.6 million by 2033. Within the healthcare sector, the placental growth factors market focuses on the diagnosis, treatment, and management of placental-related disorders and complications, including pre-eclampsia. Proteins called placental growth factors are made by the placenta during pregnancy and are essential to the growth and upkeep of a successful pregnancy. Placental growth factor (PlGF), vascular endothelial growth factor (VEGF), and other factors are among them.

The market for placental growth factors has been growing steadily due to various factors. One key driver is the increasing awareness of the importance of maternal and fetal health. There is a growing emphasis on prenatal care and the early detection of pregnancy-related complications, which has led to an increased demand for placental growth factor testing as a diagnostic tool.

Achieve Peak Productivity - Don't Delay Your Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-17647

The rising incidence of pregnancy-related complications, such as preeclampsia, gestational diabetes, and intrauterine growth restriction, has also contributed to the growth of the placental growth factors market. Placental growth factors play a crucial role in assessing and managing these complications, making them essential biomarkers in obstetric care.

Advancements in diagnostic technologies have further fueled the market growth. Improved immunoassays, molecular diagnostics, and imaging techniques enable accurate measurement and assessment of placental growth factors, enhancing the diagnosis and monitoring of placental health.

Government initiatives and support for maternal and child healthcare have also played a significant role in driving market growth. Governments worldwide are implementing programs to improve prenatal care, reduce maternal and infant mortality rates, and promote the early detection of pregnancy-related complications. This support fosters research and development in the field of placental growth factors and encourages the adoption of these tests in clinical practice.

Key Takeaways:

The placental growth factors industry in the United States is predicted to reach US$ 24.1 million by 2033, increasing at a 6.0% CAGR.
The placental growth factors industry in the United Kingdom is estimated to reach a market value of US$ 2.8 million, expanding at a CAGR of 5.7% by 2033.
During the forecast period, the placental growth factors industry in China is expected to reach a market value of US$ 5.6 million, securing a 7.0% CAGR.
The placental growth factors industry in Japan is predicted to reach US$ 2.4 million by 2033, increasing at a 5.2% CAGR.
South Korea's placental growth factors industry is predicted to achieve a market value of US$ 1.0 million, rising at a 6.7% CAGR during the forecast period.
With value share of 57.0%, ophthalmology segment dominated the placental growth factors industry in 2022.
With value share of 51.2%, the pharmaceutical and biotechnology companies dominated the placental growth factors industry in 2022.

Key Players in the Microbiopsy Industry

Trajan Scientific Australia Pty Ltd.
Vigeo
Zamar Biopsy
Medax
AprioMed
Hologic
Mammotome
M.D.L.
Histo
Changzhou Mingle Medical Equipment Co., Ltd.
Surtex Instruments Limited
STERIS
MICRO-TECH EUROPE
Boston Scientific Corporation

Key Developments:

In April 2022, Together with scientists from The University of Queensland (UQ), Trajan Scientific and Medical (Trajan, ASX:TRJ) created a portable skin microbiopsy equipment that collects tissue samples with a diameter of less than 0.5 mm. The instrument is made to gather biopsies for disorders of the skin, including skin cancer.
In January 2021, A market leader in women's health, Hologic, Inc. (Nasdaq: HOLX), has announced that it has reached an agreement to purchase privately held, commercial-stage startup Biotheranostics, Inc., which offers molecular diagnostic tests for breast and metastatic cancers.

Segmentation Analysis of the Microbiopsy Market

By Product: